City of Hope®

Annual

Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

Day 1

Summary and Wrap Up



Vivek Kaul, MD

Professor of Medicine

Center for Advanced Therapeutic Endoscopy

Division of Gastroenterology & Hepatology

University of Rochester Medical Center

President Elect, WGO

Disclosures

- Consultant for Amgen, Castle Biosciences, Cook Medical, Exact Sciences, Provation and Steris.

This presentation and/or comments will be free of any bias toward or promotion of the above referenced companies or their product(s) and/or other business interests.

This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.

This presentation has been peer-reviewed and no conflicts were noted.

Day-1: SESSION 1

NON-CME ACCREDITED SESSIONS

7:55 – 8:00 AM

AI Coordination for Open Access Colon Screening
Huzaifa Sial, MS | Careforce

8:00 – 9:30 AM

SESSION 1
Introduction: Next Gen Cancer Prevention and Detection
Moderator: N. Jewel Samadder, MD | Mayo Clinic Comprehensive Cancer Center

Opportunities for Precision Interception of Early Onset Colorectal Cancer
Stephanie Schmit, PhD, MPH | Cleveland Clinic

Early Detection and Precision Interception:
Guiding Colorectal Cancer Management with Circulating Tumor DNA (ctDNA)
Stacey A. Cohen, MD | Fred Hutch Cancer Center

KEYNOTE LECTURE
Integrating Precision Medicine into Cancer Care: Promise and Progress
Stephen B. Gruber, MD, PhD | City of Hope

Panel Discussion
Stephen B. Gruber, MD, PhD; Stacey A. Cohen, MD; Stephanie Schmit, PhD, MPH;
Michael B. Wallace, MD, MPH; Andreas M. Kaiser, MD & David Luyimbazi, MD

9:30 – 9:50 AM

What Can MedTech Learn from Pharma? The Business Perspective
Brad Maruca, MBA, MS | Deloitte

Key Points-Session 1

(Gruber, Schmit, Cohen, Maruca)

- Precision medicine-genetic testing + genomic profiling: new paradigm
- Immunotherapy for locally advanced colon ca: balance risks/benefits
- Daraxonrasib-game changer for metastatic Panc Ca (criteria)
- Vaccines in Lynch: shared peptides induce T cell immunity
- Insights into EARLY onset Colon cancer/CRC screening uptake efforts
    - Polygenic Risk Scores (PRS) + Environmental Risk Scores (ERS) {45-49 age group}
    - Education/Obesity/Research
- ctDNA is a TECHNOLOGY-strong prognostic marker
    - Tumor informed + tumor agnostic
    - Can guide Rx escalation and de-escalation
- Medtech/Pharma: Borrow, Replicate, Innovate, but don’t Duplicate
    - Evidence, Coverage, Skills gap, Data as a lever

Day-1: Session 2

9:50 – 11:00 AM

SESSION 2

Innovation & Technologies: Industry Session

Moderators: Gagandeep Singh, MD; Pashtoon Murtaza Kasi, MD, MS & Toufic Kachaamy, MD

Guardant Health | Advancing Comprehensive Genomic Profiling with Epigenomics: Guardant360 Liquid Updates and Applications
Sheila Solomon | Guardant Health

Revolution Medicines | RASONQUE: Breaking Barriers in Metastatic Pancreatic Adenocarcinoma by Targeting RAS
Caroline Ling, PharmD | Revolution Medicines

STERIS | Innovations in Diagnosis, Preservation, and Treatment of GI Cancers – Cool Science. Real Impact
Neil R. Sharma, MD | Banner MD Anderson

Key Points-Session 2

(Maruca,Solomon, Nallapareddy, Sharma)

- MedTech-Pharma
  - Evidence, Coverage/Reimbursement, Skills gap, Data
  - Idea is NOT to duplicate, but to rebuild & reimagine
- Guardant Health
  - ctDNA liquid biopsy
  - New era in cancer diagnosis/monitoring
- Revolution Medicine
  - Rasonque
  - Multiselective inhibitor
- Steris
  - Cryotherapy for EAC/Dysphagia palliation
  - COOLAID Trial
  - COLD PRIME (PDL, Immune Upregulation, Multiomics)

Day 1: Session 3

11:30 AM – 1:00 PM	**SESSION 3** ***Introduction: Endoscopic Oncology 2.0: Where Technique Meets Molecular Insight*** *Moderator:* Vivek Kaul, MD | University of Rochester Medical Center **Next Gen Endoscopic Resection in Rectal and Esophageal Cancer** Mingyan Cai, MD, PhD | Fudan University **Endoscopic Ablation: Now and the Future** Neil R. Sharma, MD | Banner MD Anderson **Measurable Residual Disease (MRD) Kinetics and Procedural Outcomes** Pashtoon Murtaza Kasi, MD, MS | City of Hope ***Panel Discussion*** Mingyan Cai, MD, PhD; Neil R. Sharma, MD; Pashtoon Murtaza Kasi, MD, MS; Steven H. Lin, MD, PhD & Venkata Muddana, MD
1:00 – 1:30 PM	**Augmented Intelligence and Human-Machine Collaboration: A Psychological Perspective** Hannah Farfour, DNP, APRN

Key Points: Session 3
(Cai, Sharma, Kasi, Farfour)

- *"It's always lonely when you are too ahead of the times…"*
    - Advanced ESD + EFTR for ESCC and Rectal Ca
    - Neoadjuvant Rx + Endoscopic resection
    - Proof of principle shown, have to generate Level 1 data
- ERCP, EUS: RFA, Microwave Ablation: Mixed Bag
    - Mechanical effect + Immune stimulation/upregulation
    - MDT protocols, high-quality data needed, Oncologic/Survival metrics
- MRD Kinetics + Procedure Outcomes
    - Technique/Procedure: removes what we see, Molecular testing measures what we can't (see)
    - High sheddars vs Low sheddars, Match kinetics to the procedure, MRD window (timing matters), Trajectory
    - MRD+ What should we do next?
- Teams win when HUMAN adds something that AI lacks
    - Automation bias/deskilling
    - Be gatekeeper, verify, invite disagreement, protect skills, OWN the decision

Day-1: Session 4

2:40 – 4:10 PM

SESSION 4

Optimizing Oncologic Outcomes: Metabolic, Endoscopic, and Biomarker-driven Strategies

Moderators: Neil R. Sharma, MD & Pashtoon Murtaza Kasi, MD, MS

Optimizing Oncologic Outcome via Active Weight Management

Rahul Pannala, MD, MPH | Mayo Clinic Comprehensive Cancer Center

Endoscopic Interventions to Optimize Pancreaticobiliary Surgical Outcomes

Vinay Chandrasekhara, MD | Mayo Clinic Comprehensive Cancer Center

Multimodal TME Assessment in the Era of AI and Precision

Haider A. Mejbel, MD | Mayo Clinic Comprehensive Cancer Center

Panel Discussion

Pashtoon Murtaza Kasi, MD, MS; Rahul Pannala, MD, MPH; Vinay Chandrasekhara, MD; Haider A. Mejbel, MD; Christina Wu, MD & Hamza Shah, DO

Key Points: Session 4
(Pannala, Chandrasekhara, Mejbel)

- Obesity and GI Cancer: Strong link, need cancer specific prevalence, MDT approach
  - Diet + Lifestyle, GLP, Endoscopy (Foregut anatomy), Surgery (severe)
  - Does managing conquering Obesity impact survival/outcome
- Endoscopy for optimizing Surgery:
  - Before surgery (accurate diagnosis/stage), During Neadjuvant Rx, After Surgery
  - Post-operative complications: Endoscopic management (bleeding to fistula closure)
- AI in GI: ADR, Molecular triage, Foundational models in computational pathology
  - Multimodal approach is better (genomics, radiology, pathology)
  - Significant challenges remain (generalizability, bias, regulatory, cost)

Thank you!



vivek_kaul@urmc.rochester.edu